激酶药物发现深度学习、AI与化学信息学方向博士研究员(科研助理,薪级 P)
PhD Position (Doctoral Candidate 10) in the Marie Skłodowska-Curie Doctoral Network ANA-KIN
原帖优先:申请材料、截止时间与资格以原帖和学校官方说明为准。
AI 中文速览
- 研究内容
- 本项目为 MSCA 博士网络 ANA-KIN 的一部分(DC10,工作包 3 - 发现),致力于开发深度学习架构,整合文本挖掘、化学信息学和生物物理描述符,以预测激酶配体的界面结合、变构特征和耐药性风险。模型将联合学习多肽和小分子模态,生成混合拟肽设计假设,并转化为指导 ANA-KIN 发现活动的财团级优先排序仪表板。研究者将与合作伙伴 VIB(比利时,Ruslan Efremov 教授)和 Skylight Therapeutics(比利时,Joshua Salafsky 博士)开展两次共计 7 个月的学术第二阶段研究(secondments)。
- 申请条件
- 申请者须持有计算机科学、人工智能、(计算)化学、生物信息学、生物制药科学或相关领域的理学硕士学位(MSc);具备机器学习和深度学习技术(如 PyTorch)的良好知识和经验;具备化学信息学和/或计算化学(如 RDKit、分子描述符、对接)的良好知识和经验;精通编程(首选 Python);具备优秀的英语口头和书面沟通能力;同时必须符合 MSCA 资助的流动性规则(在招募前 36 个月内在荷兰居住或开展主要活动的时间不得超过 12 个月且尚未获得博士学位)。
- 待遇
- 提供为期 48 个月的全职博士生(Doctoral Candidate)雇佣合同,初始合同为期一年,评估合格后延长至剩余期限。薪资为每月税前 3,204 欧元至 4,051 欧元(根据荷兰大学集体劳动协议薪级 P)。提供 8% 的假期津贴、8.3% 的年终奖、培训和职业发展支持,来自荷兰以外的候选人可能有资格享受大幅税收减免。
- 申请方式
- 请通过在线申请系统提交申请,申请截止日期为 2026 年 11 月 12 日。申请时须注明空缺职位编号和“ANA-KIN DC10”。选定的候选人可能会被邀请在 11 月最后一周至 12 月第一周参加面试。
- 材料清单
- 求职信(包含确认符合 MSCA 资格条件的声明)
- 简历
- 成绩单列表
- 两封推荐人联系方式(已同意被联系)
由 gemini-2.5-flash-lite 生成,博士岗判定置信度 100%。
岗位信息
- 截止
- (Europe/Amsterdam) 剩 28 天
- 学科
- 计算机科学
- 合同类型
- 雇佣合同
- 原文薪资
- EUR 3,204–4,051 / 月(税前)
- 税后月薪(估)
- ¥19,000–¥24,000;房租后 ¥11,100–¥16,100
- 估算假设
- 单身、无子女、雇佣合同的粗略估算,以学校 offer 为准;扣除率 25%;汇率日期 2026-10-01
- 原帖发布
- 本站收录
- 内容更新
- 原帖导师候选(待核验)
- Prof. Gerard J.P. van Westen
- 来源
- AcademicTransfer(荷兰学术招聘) · 最近核对 2026-10-15
- 详情核验
判定依据(原文摘录)
- is_phd
The Faculty of Science and Leiden Academic Centre for Drug Research (LACDR) are looking for candidates for a PhD Position (Doctoral Candidate 10) in the Marie Skłodowska-Curie Doctoral Network ANA-KIN
- english_ok
• Excellent proficiency in English (oral and written).
- bachelor_ok
• A MSc degree in Computer Science, AI, (Computational) Chemistry, Bioinformatics, Biopharmaceutical Sciences, or a relevant related field;
原文
The Faculty of Science and Leiden Academic Centre for Drug Research (LACDR) are looking for candidates for a PhD Position (Doctoral Candidate 10) in the Marie Skłodowska-Curie Doctoral Network ANA-KIN
ANA-KIN is a Marie Skłodowska-Curie Actions (MSCA) Doctoral Network funded by the European Union’s Horizon Europe programme. Over the past two decades, small-molecule kinase inhibitors have transformed cancer therapy, yet nearly all of them target the highly conserved ATP-binding site, which limits selectivity and allows resistance to emerge. ANA-KIN aims to train a new generation of interdisciplinary researchers capable of redefining kinase drug discovery beyond the ATP paradigm, by developing the experimental and computational tools, modular assays and workflows needed to systematically target non-conserved regulatory interfaces, such as kinase dimerization and substrate-binding sites. Proof-of-concept will be demonstrated on three representative kinases: EGFR, BRAF and the understudied “dark” kinase LTK.
ANA-KIN brings together 11 beneficiaries and 9 associated partners across Europe and the USA, including Aristotle University of Thessaloniki (coordinator), University of Crete, Goethe University Frankfurt, Saarland University, EPFL, CNRS, Pompeu Fabra University, VIB, KU Leuven, INSERM and Leiden University, together with industrial partners such as AstraZeneca, Novartis, Servier and Skylight Therapeutics. The network combines chemical biology, structural biophysics (single-molecule FRET, cryo-EM, nanodiscs), AI-driven drug design and cell biology in an integrated learn–design–test loop. Twelve Doctoral Candidates (DCs) will each pursue an individual research project, benefit from co-supervision across institutions and sectors, carry out two research secondments at partner organizations, and follow a structured network-wide training program covering scientific, transferable, open-science and entrepreneurial skills.
In this PhD project (DC10, Work Package 3 – Discovery), you will develop deep-learning architectures that integrate text-mined, cheminformatic, and biophysical descriptors to predict interface binding, allosteric signatures and resistance liabilities of kinase ligands. The models will learn jointly across peptide and small-molecule modalities and will be used to generate hybrid peptidomimetic design hypotheses. You will translate these models into consortium-wide prioritisation dashboards that support hit triage and analogue selection in the discovery campaigns of ANA-KIN, and work in close reciprocal feedback with DC9 (Saarland University) on structure-based and machine-learning pipelines. Model predictions will be validated prospectively with the experimental partners in the network.
The expected results are a resistance-aware AI workflow for non-ATP interface ligands, accompanied by public models, datasets and interpretable feature maps, and prospective design case studies demonstrating improved optimisation trajectories. To reinforce structural grounding and experimental validation, you will carry out two secondments: at VIB (Belgium, Prof. Ruslan Efremov; 4 months) to extract structural classes and conformational features from cryo-EM data and use them to refine model constraints, and at Skylight Therapeutics (Belgium, Dr. Joshua Salafsky; 3 months) to test model predictions using second-harmonic generation (SHG)-based conformational profiling. The project will be supervised by Prof. Gerard J.P. van Westen (Leiden University), with Prof. Ruslan Efremov and Dr. Joshua Salafsky as co-supervisors.
What you will do • Conduct original and novel research in deep learning, AI, and cheminformatics for kinase drug discovery; • Develop, benchmark and openly share models, datasets and decision-support dashboards following FAIR and open-science principles; • Collaborate closely with experimental and computational DCs in the network, and carry out two research secondments abroad (VIB and Skylight Therapeutics, Belgium); • Publish and present scientific articles at international journals and conferences; • Participate in the ANA-KIN network-wide training events, schools and outreach activities; • Contribute to educational activities; • Write a dissertation.
What you bring • A MSc degree in Computer Science, AI, (Computational) Chemistry, Bioinformatics, Biopharmaceutical Sciences, or a relevant related field; • Good knowledge of and experience with machine learning and deep-learning techniques (e.g. PyTorch); • Good knowledge of and experience with cheminformatics and/or computational chemistry (e.g. RDKit, molecular descriptors, docking); • Interest in structural biology, protein kinases and drug discovery; affinity with peptide or biophysical data is an advantage; • Highly motivated to both perform foundational research and apply the developed methods to real-world problems; creative, ‘making things work’ mentality, independent, and communicative team player; • Willingness to travel and to carry out research secondments at partner institutions abroad; • Excellent programming skills (preferably Python); • Good academic writing skills and interest in participating in educational activities; • Excellent proficiency in English (oral and written).
MSCA eligibility criteria • At the date of recruitment, candidates must not have been awarded a doctoral degree; • Mobility rule: candidates must not have resided or carried out their main activity (work, studies, etc.) in the Netherlands for more than 12 months in the 36 months immediately before the date of recruitment. Compulsory national service, short stays such as holidays, and time spent as part of a procedure for obtaining refugee status are not taken into account.
Where you will work
Leiden Academic Centre for Drug Research Our institute is a center of excellence for multidisciplinary research on drug discovery and development. Leiden University consistently ranks within the top-20 world-wide within the subject-based QS Ranking in Pharmacology and Pharmacy. At LACDR, we develop innovative scientific concepts in fundamental and translational research underlying the discovery and optimization of drugs, and personalized medicines. We aim to optimize the route to novel drugs that are both efficacious and safe, and therefore our research focuses on drug discovery and safety, bio-therapeutics, and systems biomedicine and pharmacology. State-of-the-art expertise and infrastructures ensure that we are strategically positioned in (inter)national collaborations, thus further strengthening the development of novel concepts and their application in a clinical and industry environment.
Computational Drug Discovery Research in this group, headed by Gerard van Westen, focusses on computational methods integrated in different parts of the drug discovery process. More specifically, topics include innovative treatments for cancer, kinase and GPCR drug discovery, proteochemometrics, selectivity and polypharmacology modeling, allosteric modulation, drug resistance modeling, de novo molecular design, and novel methods in the domain of machine learning. For more information see: http://www.cddl.nl
Research at our faculty The Faculty of Science is a world-class faculty where staff and students work together in a dynamic international environment. It is a faculty where personal and academic development are top priorities. Our people are committed to expand fundamental knowledge by curiosity and to look beyond the borders of their own discipline; their aim is to benefit science, and to make a contribution to addressing the major societal challenges of the future.
The research carried out at the Faculty of Science is diverse, ranging from artificial intelligence, computer science, mathematics, astronomy, physics, chemistry and bio-pharmaceutical sciences to biology and environmental sciences. The faculty has grown strongly in recent years and now has more than 2,700 staff and almost 6,000 students. We are located in the heart of the Bio Science Park, one of Europe’s largest science parks, where academia and industry meet. For more information, see http://www.science.leidenuniv.nl .
What we offer We offer a full-time appointment for 48 months as a Doctoral Candidate within the MSCA Doctoral Network ANA-KIN, starting late 2026. The appointment is initially for one year; after a positive evaluation of the progress of the research, personal capabilities and compatibility, the appointment will be extended for the remaining period. Salary ranges from € 3.204,- tot € 4.051,- gross per month (pay scale P in accordance with the Collective Labor Agreement for Dutch Universities).
Leiden University offers an attractive benefits package with additional holiday (8%) and end-of-year bonuses (8.3%), training and career development. Our individual choices model gives you some freedom to assemble your own set of terms and conditions. Candidates from outside the Netherlands may be eligible for a substantial tax break.
All our PhD students are embedded in the Leiden University Graduate School of Science. Our graduate school offers several PhD training courses at three levels: professional courses, skills training and personal effectiveness. In addition, advanced courses to deepen scientific knowledge are offered by the research school. As an ANA-KIN Doctoral Candidate you will also follow the network’s training program, including summer schools, workshops and an industrial immersion workshop, and your progress will be monitored by a Thesis Advisory Committee including an independent mentor.
What we value Promoting an inclusive community is central to Leiden University’s values and vision. We strive to be an open community in which all students and staff members feel valued and respected, and are able to fully develop themselves. We consider an inclusive academic environment, where students and staff can share their experiences and viewpoints, to be essential for the development of talent.
Want to apply or find out more? Inquiries about the research area can be made to Prof. Gerard van Westen, gerard@lacdr.leidenuniv.nl. If you have any questions about the procedure, please contact Brigitte Kraakman, b.p.m.kraakman@lacdr.leidenuniv.nl. To apply for this vacancy, please submit your application online via the blue button below. Please ensure that you upload the following additional documents quoting the vacancy number and “ANA-KIN DC10”: • application letter (including a statement confirming that they meet the MSCA eligibility criteria) • curriculum vitae • a list of grades • two references (who have agreed to be contacted)
Only applications received no later than November 12th can be considered. The selection procedure will take place in November. Selected candidates may be invited for an interview in the last week of November / 1st week of December, during which you are kindly requested to be available. • Acquisition in response to this vacancy is not appreciated. If you nevertheless choose to send us CVs, no rights can be derived from this. #LI-Hybrid